Article Details
Retrieved on: 2022-06-05 15:52:35
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody. Safety results suggest ...
Article found on: www.miragenews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here